Blog | Enquirer News

YouTube Adds AI Upscaling and Shopping Features for TVs

Tech

-

YouTube Adds AI Upscaling and Shopping Features for TVs

AI-Powered Video Enhancements Coming to TV Viewers

YouTube has unveiled a series of new features designed to enhance the viewing experience on television screens, including AI upscaling for low-resolution videos and a shopping tool that allows viewers to instantly purchase products seen in videos. The company confirmed that it will begin automatically upscaling videos uploaded below 1080p, boosting them to high definition, with 4K upscaling support planned “in the near future.”

“Creators will retain complete control over their library, as both original files and original video resolution will be kept intact,” YouTube said in its announcement. Both creators and viewers will have the option to opt out of the enhancement, and videos will be clearly labeled under settings when AI-based “super resolution” is active.

Balancing AI Innovation and Creator Control

YouTube’s move follows industry trends as nearly all major TV brands now integrate their own AI upscaling technology, and Nvidia’s Shield TV already offers similar functionality. The opt-out feature is a direct response to creator concerns that platforms were applying automated video enhancements without consent, sometimes causing unwanted artifacts or distortions.

According to YouTube spokesperson Veronica Navarrete, the new AI upscaling will apply only to videos originally uploaded in 240p to 720p resolutions. It will not affect older videos that creators have already upgraded to 1080p manually. This ensures that legacy content remains untouched while offering improved visuals for older, lower-quality uploads.

Enhanced Shopping and Creator Tools

In addition to visual upgrades, YouTube is introducing instant shopping capabilities for TV viewers. Videos featuring tagged products will now display a QR code that viewers can scan with their phones to buy items directly from the product page. The company is also testing a feature that lets creators highlight products at specific, timed moments within their videos.

Thumbnail quality is getting a major upgrade as well, with the platform expanding file size limits from 2MB to 50MB to support 4K images. Select creators are also participating in tests for larger video uploads, signaling YouTube’s continued focus on high-quality visual presentation for TV audiences.

Improved Navigation and Discovery on TVs

The update includes new immersive homepage previews for TV apps, making it easier for users to browse favorite channels, and a refreshed “Shows” section that organizes series-like playlists into bingeable seasons, similar to streaming platforms like Netflix. YouTube has also improved contextual search, prioritizing videos from the specific channel being browsed rather than displaying unrelated platform-wide results.

“The TV screen is our fastest-growing surface,” YouTube said, emphasizing that its goal is to “deliver features that make creator content shine.” The combination of AI-driven enhancements, shoppable content, and interface updates reflects YouTube’s broader strategy to position itself as both a premium entertainment hub and a competitive e-commerce platform on the largest screen in the home.

UnitedHealth Group Posts Strong Q3 2025 Results

Finance

-

0

UnitedHealth Group Posts Strong Q3 2025 Results

Company Reaffirms Growth and Raises Full-Year Outlook

UnitedHealth Group (NYSE: UNH) reported solid financial performance for the third quarter of 2025, demonstrating progress on its strategic priorities and a return to sustained growth. The company also raised its full-year earnings guidance, signaling confidence in continued momentum heading into 2026.

“We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond, and our results this quarter reflect solid execution toward that goal,” said Stephen Hemsley, chief executive officer of UnitedHealth Group.

The company now expects net earnings of at least $14.90 per share and adjusted net earnings of at least $16.25 per share for 2025, reflecting an improved outlook following a robust third quarter.

Third Quarter 2025 Highlights

UnitedHealth Group reported consolidated revenues of $113.2 billion, representing a 12% year-over-year increase. Earnings from operations totaled $4.3 billion, with a net margin of 2.1%. Adjusted earnings per share reached $2.92, while GAAP EPS came in at $2.59.

The company’s medical care ratio (MCR) stood at 89.9%, consistent with expectations, while the operating cost ratio was 13.5%, reflecting ongoing investments to support long-term expansion.

Business Segment Performance

The UnitedHealthcare segment delivered particularly strong results, with revenues rising 16% year-over-year to $87.1 billion. Growth was driven by continued strength in the Medicare & Retirement and Community & State businesses. UnitedHealthcare served 50.1 million consumers in the United States, an increase of 795,000 compared to the same period last year.

Meanwhile, Optum posted revenues of $69.2 billion, up 8% year-over-year, supported primarily by gains in Optum Rx. The business continues to expand its service capabilities and integration across the UnitedHealth Group portfolio.

Financial Position and Outlook

As of September 30, 2025, UnitedHealth Group maintained a debt-to-capital ratio of 44.1%, unchanged from the second quarter and inclusive of the recently completed Amedisys acquisition on August 14, 2025. The company emphasized its focus on balancing growth investments with disciplined financial management to support its long-term mission.

With strong performance across its core segments and an upgraded earnings forecast, UnitedHealth Group enters the final quarter of 2025 positioned for continued revenue expansion, operational stability, and enhanced shareholder value.

GLP-1 Drugs Linked to Decline in U.S. Obesity Rates

Health

-

0

GLP-1 Drugs Linked to Decline in U.S. Obesity Rates

New Data Shows Promising Shift in National Obesity Trends

A new Gallup National Health and Well-Being Index survey reveals that the growing use of injectable obesity treatments, such as Ozempic, Wegovy, Zepbound, and Mounjaro, is correlated with a measurable decline in U.S. obesity rates. According to the data, 37% of American adults are now classified as obese — down from a peak of 39.9% three years ago.

The survey highlights that 12.4% of respondents are currently using GLP-1 medications, more than double the 5.8% reported in February 2024. These drugs, first approved for obesity treatment in 2021, act on the brain and hormonal systems to reduce appetite and slow digestion, marking a new phase in the nation’s decades-long fight against obesity.

GLP-1 Medications: A Turning Point in Obesity Care

Experts describe GLP-1 agonists as a “watershed moment” in addressing obesity and related conditions such as diabetes. The survey recorded the highest-ever rate of diabetes at 13.8%, underscoring the urgency for effective weight management strategies. While public health campaigns and diet trends have struggled to reverse obesity growth in the past, GLP-1 drugs appear to be making an impact — albeit gradually.

Obesity rates have fallen most notably among adults aged 40 to 64, who are also the most frequent users of GLP-1 treatments. In this age group, the obesity rate dropped by five points to 42.8%. The survey also shows that women are using these medications at higher rates than men and report greater weight loss outcomes as a result.

Access and Affordability Remain Major Barriers

Despite their success, access to GLP-1 medications remains uneven. Dr. Fatima Cody Stanford, an obesity specialist at Harvard University, warned that many private insurers plan to discontinue coverage for these drugs in the coming year. Without insurance, patients could face costs of around $500 per month out of pocket.

Stanford noted that those with comprehensive coverage have seen the greatest benefits, but the anticipated loss of insurance support may limit broader public health impact. Drugmakers are currently developing oral pill versions of GLP-1 therapies, though affordability challenges are expected to persist even as these alternatives reach the market.

Slow but Encouraging Progress

While the decline in obesity rates is modest, researchers say it marks a pivotal shift after decades of steady increases. GLP-1 medications are helping many Americans achieve meaningful weight loss, potentially signaling the beginning of a new era in metabolic health. However, experts caution that sustained progress will depend on ensuring equitable access to these treatments and addressing underlying socioeconomic disparities in obesity care.

Novartis to Acquire Avidity Biosciences in $12 Billion Deal

Business

-

0

Novartis to Acquire Avidity Biosciences in $12 Billion Deal

Acquisition Strengthens Novartis’ RNA Therapeutics Portfolio

Swiss pharmaceutical leader Novartis has announced plans to acquire Avidity Biosciences in a deal valued at approximately $12 billion, marking one of the largest biotechnology acquisitions of the year. The transaction, revealed Sunday, underscores Novartis’ growing ambition in RNA-based therapeutics and its strategy to expand its drug development pipeline across key disease areas.

Under the agreement, Novartis will pay $72 per share in cash to Avidity shareholders—a 46% premium over Avidity’s closing stock price of $49.15 on Friday. The deal is expected to close during the first half of 2026, following the planned spinout of Avidity’s early-stage precision cardiology programs.

Novartis Eyes RNA Therapeutics Leadership

“The Avidity team has built robust programs with industry-leading delivery of RNA therapeutics to muscle tissue,” said Vas Narasimhan, CEO of Novartis, in a company statement. “We look forward to developing these programs to meaningfully change the trajectory of diseases for patients.”

Avidity is known for pioneering a new generation of RNA therapeutics known as antibody oligonucleotide conjugates (AOCs). These treatments combine antibodies with RNA-based molecules to precisely target and modulate gene expression in muscle tissue—an innovation that could redefine therapies for muscular, cardiovascular, and genetic disorders.

Following the acquisition announcement, Novartis raised its compound annual growth rate (CAGR) forecast for sales between 2024 and 2029 from 5% to 6%, reflecting the expected revenue potential from Avidity’s pipeline and platform technologies.

Strategic Expansion and U.S. Investment Push

The acquisition comes as Novartis intensifies its research and development (R&D) initiatives globally. Earlier this year, the company pledged a $23 billion investment to strengthen its U.S. infrastructure, including the construction of a second R&D hub in San Diego. The move aims to accelerate innovation and attract top talent in the American biotech ecosystem.

In addition to the Avidity purchase, Novartis has forged partnerships with Anthos Therapeutics and Regulus Therapeutics to advance treatments for cardiovascular and kidney diseases. These collaborations highlight the company’s broader effort to diversify its therapeutic portfolio and sustain long-term growth through precision medicine and advanced biological platforms.

Market Reaction and Outlook

Avidity Biosciences’ stock, which has surged nearly 70% year-to-date, closed at $49.15 on Friday with a market capitalization of about $7.2 billion. Following the announcement, shares are expected to jump as investors react to the acquisition premium. Novartis stock closed at $130.36 on the same day.

Analysts say the deal represents a major step for Novartis as it positions itself among leaders in the RNA therapeutics race, an area attracting growing interest from global pharmaceutical firms. Pending regulatory approval and the successful integration of Avidity’s technologies, the acquisition could significantly boost Novartis’ innovation capacity and reinforce its leadership in next-generation drug development.

With this acquisition, Novartis signals its confidence in RNA therapeutics as a transformative frontier in modern medicine—one that could reshape treatment options for patients with previously untreatable diseases.

Keywords: Novartis, Avidity Biosciences, RNA therapeutics, antibody oligonucleotide conjugates, Vas Narasimhan, biotechnology acquisition, precision medicine, pharmaceutical industry, R&D investment, San Diego hub

Hurricane Melissa Becomes Category 5, Poised for Record Jamaica Landfall

World

-

0

Hurricane Melissa Becomes Category 5, Poised for Record Jamaica Landfall

Historic Storm Brings 165 mph Winds and Catastrophic Rainfall

Hurricane Melissa has rapidly intensified into a Category 5 storm, unleashing 165 mph winds and torrential rainfall as it bears down on Jamaica. The National Hurricane Center (NHC) has warned that the storm will bring “extensive infrastructure damage,” with up to 40 inches of rain and storm surges as high as 13 feet expected along parts of the coast.

Melissa’s outer bands are already battering Jamaica with high winds and heavy rain. Authorities have issued mandatory evacuation orders for vulnerable coastal areas ahead of what could become the strongest hurricane ever to hit the country. So far, the storm has claimed at least four lives—three in Haiti and one in the Dominican Republic.

Rapid Intensification Linked to Warming Oceans

The hurricane’s explosive growth stunned forecasters. Melissa’s winds increased by 70 mph in just 24 hours over the weekend—an example of extreme rapid intensification that scientists say is becoming more frequent due to warming oceans and higher atmospheric moisture fueled by fossil fuel pollution.

The storm is now the 45th Category 5 hurricane on record in the Atlantic and the third of this season. As global sea surface temperatures rise, hurricanes are gaining strength more quickly and producing heavier rainfall, leading to increased flooding and destruction in coastal regions.

Jamaica Faces Strongest Storm Since Hurricane Gilbert

Melissa may be Jamaica’s most powerful hurricane since Hurricane Gilbert in 1988, which killed at least 40 people and devastated much of the island. Authorities say the country has made significant strides in strengthening its infrastructure since then—but the coming days will test those improvements like never before.

“We’re certainly better prepared than we would have been in the ’80s,” said Matthew Samuda, Jamaica’s Minister of Water, Environment and Climate Change, in an interview with CNN. “But when you speak about 160 mph winds, we’ve never tested our new infrastructure in that regard.” Gilbert’s winds reached 135 mph when it made landfall 37 years ago.

Power utilities and emergency crews have been put on high alert. Authorities have reinforced hospitals, communication lines, and flood defenses, though officials acknowledge that 160 mph sustained winds and massive storm surges could cut off entire communities.

Life-Threatening Flooding and Storm Surge Expected

The NHC warned that the storm’s impact could be catastrophic. Storm surges between nine and 13 feet are expected to inundate coastal regions, while mountainous areas could face flash flooding and mudslides. The government urged residents to seek higher ground immediately and avoid traveling through flood-prone zones.

With the island bracing for the full force of the storm, emergency shelters have opened across Jamaica, and international aid agencies are preparing to mobilize relief operations once conditions allow. As Melissa approaches landfall, forecasters warn the coming hours will be decisive for both Jamaica’s safety and its resilience against climate-fueled megastorms.

Fujifilm Unveils X-T30 III with New Processor and Film Simulation Dial

Tech

-

0

Fujifilm Unveils X-T30 III with New Processor and Film Simulation Dial

Refined Design, Familiar Sensor, and Smarter AI Autofocus

Fujifilm has officially introduced the X-T30 III, the latest version of its compact interchangeable-lens camera. While not a full redesign, the update brings meaningful upgrades powered by the company’s new X-Processor 5, giving the camera faster performance, enhanced autofocus, and expanded video capabilities.

The X-T30 III retains the 26.1-megapixel X-Trans CMOS 4 sensor found in its predecessor, the X-T30 II, but introduces a more powerful processing engine that improves both image handling and shooting flexibility. One of the most noticeable physical changes is the replacement of the traditional mode dial with a Film Simulation dial — a feature inspired by higher-end models like the X-T50.

This new dial offers quick access to 20 film simulation modes, including classic Fujifilm looks like Velvia, Provia, and Acros, plus three customizable presets. Users can fine-tune grain, color tone, highlights, and saturation to create their own digital “film recipes.”

Enhanced Video and AI Features

The faster X-Processor 5 enables the X-T30 III to step up its video capabilities considerably. The camera can now record 10-bit 6.2K video at 30fps, while 4K shooting reaches up to 60fps, and 1080p slow-motion climbs to 240fps. These improvements make the compact camera more viable for hybrid creators who alternate between stills and motion work.

On the autofocus side, Fujifilm has brought over its AI-driven subject detection system from the flagship X-series cameras. The X-T30 III can recognize and track people, animals, birds, cars, trains, insects, and even drones. Face and eye detection are also faster and more reliable than before — a welcome addition for portrait and event photographers.

Despite these advances, the camera still lacks in-body image stabilization (IBIS), a feature reserved for the higher-end X-T50. However, Fujifilm promises better battery performance, offering up to 425 shots per charge in Economy Mode, along with the convenience of a built-in pop-up flash.

Classic Style Meets Modern Connectivity

Aimed primarily at photography enthusiasts, the X-T30 III keeps the retro design that defines Fujifilm’s mirrorless lineup. The new model also integrates seamlessly with the brand’s Instax Link printers, allowing users to print cropped shots in square or wide instant film formats directly from the camera.

Available in three finishes — all black, black and silver, and black with charcoal silver — the X-T30 III stays true to Fujifilm’s blend of style and performance. The camera supports both Wi-Fi and Bluetooth for easy image transfer and remote shooting.

Pricing and Availability

The Fujifilm X-T30 III will be released in November 2025 at a starting price of $999.95 (body only), which is about $100 more than its predecessor. A kit bundle featuring the new XC 13–33mm f/3.5–5.6 OIS lens will follow in mid-December for $1,149.95. Preorders are now open at major retailers including B&H and Adorama.

While not revolutionary, the X-T30 III’s mix of modern processing power, creative film looks, and enhanced autofocus makes it a strong mid-tier option for photographers seeking the Fujifilm experience in a compact, affordable package.

Covid Vaccines May Boost Cancer Immunotherapy Success, Study Finds

Health

-

0

Covid Vaccines May Boost Cancer Immunotherapy Success, Study Finds

Early Research Suggests mRNA Shots Could Help Patients Live Longer

New research presented Sunday at the European Society for Medical Oncology conference in Berlin suggests that mRNA Covid vaccines may enhance the effectiveness of cancer immunotherapy — potentially helping patients live significantly longer.

The study, led by researchers from the University of Texas MD Anderson Cancer Center, found that cancer patients who received an mRNA Covid vaccine within 100 days before beginning immunotherapy nearly doubled their median survival time compared with those who did not get vaccinated. The findings are still early and have not yet undergone a Phase 3 clinical trial, but oncologists say the implications are striking.

“I am cautiously optimistic,” said Dr. Stephanie Dougan, an associate professor of cancer immunology at the Dana-Farber Cancer Institute, who was not involved in the research. “There is a scientific logic to why this could work.”

Vaccines That “Superdrive” the Immune System

The study’s co-lead author, Dr. Adam Grippin, explained that the mRNA Covid vaccines may help prime the immune system, making it more responsive to immunotherapy drugs — treatments that stimulate the body to identify and destroy cancer cells.

Of more than 1,000 patients with advanced non-small cell lung cancer treated with immunotherapy between 2019 and 2023, those who received an mRNA Covid vaccine lived a median of three years, compared with just over 1.5 years for unvaccinated patients. Among patients with metastatic melanoma, vaccinated individuals also showed significantly better survival, with some still alive more than three years after treatment began.

In laboratory tests on mice, the team observed a similar response. “It superdrives the immune system against tumors,” Grippin said, suggesting that the vaccines may create a “beacon” that enhances immune recognition of cancer cells.

A Possible “Goldilocks Zone” for Immune Activation

Only about 20% of patients currently benefit from immunotherapy, leaving researchers searching for ways to increase its success rate. Past efforts to stimulate the immune system have often gone too far or not far enough — either triggering damaging inflammation or failing to produce a sufficient response.

According to Dougan, mRNA vaccines might strike the right balance. “Maybe we just needed something that was medium-strong, and this could potentially be it,” she said, while emphasizing that further research is essential to confirm the findings and understand how vaccines interact with tumor biology.

Grippin and his team are now preparing to launch a Phase 3 clinical trial to validate their results in a larger population and across different types of cancer.

Next Steps and Broader Implications

mRNA vaccine technology is already being explored in oncology, with several clinical trials underway for personalized cancer vaccines designed to target unique tumor mutations. Others aim at common cancer genes, including those linked to pancreatic and melanoma tumors.

If confirmed, the new findings could reshape how doctors approach immunotherapy — potentially combining existing mRNA vaccines with cancer treatments to improve outcomes for patients with advanced disease. As Dougan noted, “There is growing excitement around the possibility that something designed for infectious disease might also unlock new frontiers in cancer therapy.”

U.S. Home Sales Climb to Seven-Month High as Mortgage Rates Fall

Finance

-

0

U.S. Home Sales Climb to Seven-Month High as Mortgage Rates Fall

Lower Rates and Rising Inventory Boost Market Activity in September

Sales of previously owned homes in the United States rose 1.5% in September compared with August, reaching a seasonally adjusted annual rate of 4.06 million units, according to the National Association of Realtors (NAR). While the figure came in just shy of analysts’ expectations, it represents the highest pace of sales in seven months and a 4.1% increase from the same period last year.

Regionally, the South and Northeast recorded the strongest annual gains, while sales in the West led the month-over-month increase. The Midwest was the only region to post a slight monthly decline. Since the data is based on closings, most of these transactions reflect contracts signed in July and August, when mortgage rates had already begun to ease.

Falling Mortgage Rates Drive Activity

The average rate on a 30-year fixed mortgage started July at 6.67% and has since fallen to 6.17%, according to Mortgage News Daily. This drop in borrowing costs is helping to restore affordability for many buyers.

“As anticipated, falling mortgage rates are lifting home sales,” said Lawrence Yun, NAR’s chief economist. “Improving housing affordability is also contributing to the increase in sales.”

Even with the improvement, affordability remains a challenge as home prices continue to climb. The median home price in September reached $415,200 — a 2.1% rise from a year earlier and the 27th consecutive month of annual price growth. Home values are now 53% higher than before the pandemic.

Inventory Rebounds but Still Tight

Housing inventory rose 14% from a year earlier to 1.55 million units at the end of September, matching a five-year high but still below pre-pandemic levels. At the current pace of sales, this represents a 4.6-month supply — short of the six-month mark considered a balanced market.

“Many homeowners are financially comfortable, resulting in very few distressed properties and forced sales,” Yun noted. “Home prices continue to rise in most parts of the country, further contributing to overall household wealth.”

Despite more listings, tight supply continues to favor sellers. Homes are taking longer to sell, with properties spending an average of 33 days on the market, up from 28 a year ago. About 30% of all transactions were made in cash, reflecting strong demand from investors and affluent buyers.

Luxury Market Leads, First-Time Buyers Gain Ground

High-end homes drove much of September’s activity. Sales of properties priced above $1 million jumped 20% year-over-year, compared with a modest 3% gain for homes under $100,000.

First-time homebuyers also made modest progress, comprising 30% of total sales — up from 26% a year ago. Falling mortgage rates appear to be easing the entry barrier slightly for new buyers after years of record-high prices and rate volatility.

While the market remains far from pre-pandemic norms, September’s rebound signals a potential turning point. With mortgage rates at their lowest in months and inventory slowly improving, economists expect continued momentum heading into the final quarter of the year.

Major Study Maps Physical Side Effects of 30 Antidepressants

Health

-

0

Major Study Maps Physical Side Effects of 30 Antidepressants

Largest Analysis Yet Offers New Data on Heart, Weight, and Cholesterol Risks

A sweeping new study from King’s College London has compared the physical side effects of 30 common antidepressants, offering the most comprehensive look yet at how these medications impact the body. Published this week in The Lancet, the analysis combines data from more than 150 clinical trials involving over 58,000 patients.

The findings quantify, for the first time, the effects of different antidepressants on weight, heart rate, blood pressure, and cholesterol. “It’s never been done at this scale before,” said lead author Dr. Toby Pillinger, a psychiatrist at King’s College London. “No one’s ever put specific numbers to the amount of weight you’ll put on or how much your cholesterol might go up.”

SSRIs Show Fewer Physical Effects

The research found that selective serotonin reuptake inhibitors (SSRIs)—such as Zoloft and Prozac, the most prescribed antidepressants in the U.S.—tend to have fewer physical side effects compared with older drug classes.

By contrast, some tricyclic antidepressants were linked to more pronounced impacts. For example, nortriptyline users experienced average heart rate increases up to 20 beats higher than those taking the SSRI fluvoxamine. In terms of weight, changes ranged from losses to gains of around four pounds depending on the medication.

Dr. Pillinger emphasized that no single antidepressant is universally “best” or “worst.” “One drug that’s problematic for one person might work perfectly for another,” he said. “The goal is to match treatment to each individual’s health profile and preferences.”

Tools to Personalize Treatment

To help with that, Pillinger’s team created a free digital tool for clinicians that organizes antidepressants by side-effect profiles. The platform allows doctors and patients to build a “menu” of treatment options based on existing health conditions and which side effects are most important to avoid.

Dr. Nina Kraguljac, a psychiatrist at Ohio State University and chair of the American Psychiatric Association’s Council on Research, called the study “well-done and largely reassuring.” She noted that “side effects alone should not guide treatment decisions,” since the findings reflect population averages rather than individual experiences.

Limitations and Context

The study’s data came primarily from eight-week trials, even though most antidepressant users stay on medication for months or years. It also excluded some key side effects, including sexual dysfunction, digestive issues, and “emotional blunting,” which often influence whether patients continue treatment.

Dr. David Hellerstein, a psychiatry professor at Columbia University, said the results reinforce that “most of these drugs seem quite safe on a lot of physical parameters, especially the newer ones like SSRIs and SNRIs.” However, he cautioned that side effects can still be important for certain patients and might shape which medication is prescribed.

Hellerstein added that side effects can sometimes be beneficial, depending on the patient’s condition. “If someone lost a lot of weight due to depression, an antidepressant that increases weight could actually be helpful,” he said. “That’s not a side effect—that’s a therapeutic effect.”

Overall, experts agree the study provides valuable data to help doctors personalize antidepressant treatment, balancing mental health benefits with physical well-being.

Meta Cuts 600 AI Jobs as Superintelligence Lab Restructures

Business

-

0

Meta Cuts 600 AI Jobs as Superintelligence Lab Restructures

Layoffs Follow Company’s Push for Efficiency and Reorganization

Meta is laying off around 600 employees from its superintelligence lab as part of a broader restructuring of its artificial intelligence operations, according to a memo from the company’s chief AI officer, Alexandr Wang, obtained by Axios on Wednesday. The tech giant confirmed the accuracy of the report to TechCrunch but declined to provide additional comment.

The cuts mark another shift in Meta’s long-term AI strategy as it competes with major rivals like OpenAI, Anthropic, and Google in the race to build advanced AI systems. The move comes after an aggressive hiring spree earlier this year, during which Meta reportedly recruited more than 50 top researchers from competing firms, offering multimillion-dollar compensation packages to lure them away.

“Fewer Conversations, More Impact”

In the memo to employees, Wang said the restructuring is meant to streamline decision-making and give remaining team members more autonomy and influence. “By reducing the size of our team, fewer conversations will be required to make a decision, and each person will be more load-bearing and have more scope and impact,” he wrote.

The comments align with Meta CEO Mark Zuckerberg’s ongoing “year of efficiency” campaign, a corporate mantra that has become synonymous with cost-cutting and organizational consolidation. Since 2023, Meta has trimmed thousands of roles across multiple divisions, positioning itself as a leaner and faster-moving company focused on profitability and technological innovation.

Reorganization, Not Retrenchment

Despite the layoffs, sources familiar with the matter told Axios that Meta’s overall headcount is unlikely to shrink significantly. The company said most of the employees affected by the cuts will have opportunities to transfer into other roles within Meta’s broader AI and infrastructure divisions.

The reorganization reflects Meta’s shifting priorities as it seeks to consolidate overlapping research projects and strengthen coordination across its AI units. The company has been investing heavily in building general-purpose AI models and integrating them into products like Facebook, Instagram, and its metaverse applications.

Meta’s Broader AI Ambitions

Meta’s AI strategy has become increasingly ambitious, with efforts to catch up to competitors in both foundational model development and applied AI products. The company’s superintelligence lab, which focuses on long-term AI safety and advanced model alignment, was established to push Meta closer to the frontier of artificial general intelligence (AGI).

While the restructuring may slow certain projects in the short term, analysts suggest it could help Meta concentrate resources on its most promising research areas, reducing internal redundancy and accelerating the rollout of next-generation AI tools.

For now, Meta continues to balance its dual priorities — maintaining profitability and staying competitive in the AI arms race — as it navigates one of the most transformative periods in its history.